+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opium (Opioid) Addiction - Pipeline Review, H2 2018

  • ID: 4620352
  • Drug Pipelines
  • 121 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adapt Pharma Ltd
  • BioCorRx Inc
  • Fab’entech SA
  • Insys Therapeutics Inc
  • Novartis AG
  • Orexo AB
  • MORE
Opium (Opioid) Addiction - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights:

This latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 6, 2, 18, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adapt Pharma Ltd
  • BioCorRx Inc
  • Fab’entech SA
  • Insys Therapeutics Inc
  • Novartis AG
  • Orexo AB
  • MORE
Introduction

Opium (Opioid) Addiction - Overview

Opium (Opioid) Addiction - Therapeutics Development

Opium (Opioid) Addiction - Therapeutics Assessment

Opium (Opioid) Addiction - Companies Involved in Therapeutics Development

Opium (Opioid) Addiction - Drug Profiles

Opium (Opioid) Addiction - Dormant Projects

Opium (Opioid) Addiction - Discontinued Products

Opium (Opioid) Addiction - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Opium (Opioid) Addiction - Pipeline by Adapt Pharma Ltd, H2 2018

Opium (Opioid) Addiction - Pipeline by Addex Therapeutics Ltd, H2 2018

Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2018

Opium (Opioid) Addiction - Pipeline by Fab’entech SA, H2 2018

Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2018

Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H2 2018

Opium (Opioid) Addiction - Pipeline by Novartis AG, H2 2018

Opium (Opioid) Addiction - Pipeline by Omeros Corp, H2 2018

Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by Orexo AB, H2 2018

Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by Serina Therapeutics Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, H2 2018

Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H2 2018

Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2018

Opium (Opioid) Addiction - Dormant Projects, H2 2018

Opium (Opioid) Addiction - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adapt Pharma Ltd
  • Addex Therapeutics Ltd
  • Aoxing Pharmaceutical Company Inc
  • BioCorRx Inc
  • BioDelivery Sciences International Inc
  • Camurus AB
  • Fab’entech SA
  • Indivior Plc
  • Insys Therapeutics Inc
  • iX Biopharma Ltd
  • Novartis AG
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexo AB
  • Pfizer Inc
  • Relmada Therapeutics Inc
  • Serina Therapeutics Inc
  • Syntropharma Ltd
  • Titan Pharmaceuticals Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4620352
Adroll
adroll